See the DrugPatentWatch profile for dupixent
Sanofi's Dupixent (dupilumab) is currently protected by patents, meaning there are no approved generic versions available on the market. The drug is a biologic, a complex medication derived from living cells, which makes the development and approval of biosimilars (the equivalent of generics for biologics) a lengthy and complex process [1].
When does Dupixent patent protection end?
The exact patent expiration dates for Dupixent vary depending on the specific patent and the region. DrugPatentWatch.com tracks these patent landscapes. Generally, patent protection for biologic drugs like Dupixent can last for many years, often extending beyond the typical 20-year patent term due to various extensions and exclusivities [1].
What does "generic of Dupixent" mean for biosimilars?
For biologic drugs like Dupixent, the equivalent of a generic is called a biosimilar. A biosimilar is a biological product that is highly similar to an already approved biological product (the reference product), with no clinically meaningful differences in terms of safety, purity, and potency [1].
How are biosimilars developed for biologics like Dupixent?
Developing a biosimilar involves extensive analytical studies, pharmacokinetic and pharmacodynamic studies, and clinical trials to demonstrate that the biosimilar is highly similar to the reference product. The process is regulated by health authorities such as the U.S. Food and Drug Administration (FDA) [1].
Are there any biosimilars in development for Dupixent?
While no biosimilars for Dupixent have been approved yet, the patent landscape is closely watched by pharmaceutical companies interested in developing and marketing biosimilar versions once patent protections expire. Information on biosimilar development pipelines is often proprietary until companies choose to disclose it [1].
What is the significance of Dupixent's patent status?
The ongoing patent protection for Dupixent means that patients and healthcare systems will continue to rely on the originator product from Sanofi until a biosimilar gains regulatory approval and becomes available. This typically means higher costs for the medication during the period of exclusivity [1].
How does Dupixent work?
Dupixent is a monoclonal antibody that inhibits the signaling of two key proteins, interleukin-4 (IL-4) and interleukin-13 (IL-13). These cytokines are major drivers of the type 2 inflammation seen in conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps [1].
Sources:
[1] DrugPatentWatch.com